Healthcare costs of IBD have shifted from hospitalization and surgery towards anti-TN

The introduction of anti tumor necrosis factor-I therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases following the introduction of these drugs.


More...